Side effects · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher any side effect compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
1 finding from 1 review
Nausea · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ nausea compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
1 finding from 1 review
Vomiting · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ vomiting compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
1 finding from 1 review
Specific side effects ‐ spotting/bleeding after treatment · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) leads to higher specific side effects ‐ spotting/bleeding after treatment compared with low‐dose mifepristone (< 25 mg) (high certainty).
1 finding from 1 review
Menses ‐ early · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with low‐dose mifepristone (< 25 mg) (low certainty).
1 finding from 1 review
Menses ‐ delay · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
1 finding from 1 review
Disease control (time when steroid could be discontinued) · bullous pemphigoid
1 finding from 1 review
Mortality at 1 year · bullous pemphigoid
It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Malhotra 2008: betamethasone oral mini-pulse - transient oedema over the face (7), oedema over hands and feet (4), epigastric discomfort (7), weakness/fatigue (5), loose stools (1), headache…
1 study · 22 participants
GRADE not reported
Investigator‐ or physician‐rated global assessment of disease severity · People with erosive oral lichen planus
Betamethasone oral mini-pulse therapy led to higher physician Global Assessment (clinical severity, 0-12 score) compared with topical triamcinolone acetonide 0.1% paste; GRADE not reported.
1 finding from 1 review
Change in ulcer size · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review